Expert Perspectives of a 67-Year-Old Man with Metastatic HER2+ Gastric Cancer

John Marshall, MD, reviews the case of a patient with metastatic HER2+ (human epidermal growth factor receptor 2) gastroesophageal junction cancer.

An expert in gastric cancers describes when and for whom molecular testing should be done in patients with metastatic HER2+ gastric cancer, and which tests are move relevant to treatment decision-making.

Dr John Marshall discusses frontline systemic treatment options for metastatic HER2+ gastroesophageal junction cancer and gastric cancer in general.

John Marshall, MD, reviews options for second- and later line therapies and considerations for treatment sequencing in patients with HER2+ gastric cancers.

Dr John Marshall discuss the DESTINY-Gastric01 trial and the implications of the study results to clinical practice for HER2+ metastatic gastric cancer.

An expert in gastric cancers provides insight on the recent advances and future directions for the management of locally advanced and metastatic gastric cancers.